Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) EBT Margin (2018 - 2023)

Denali Therapeutics (DNLI) has disclosed EBT Margin for 6 consecutive years, with 41.52% as the latest value for Q4 2023.

  • On a quarterly basis, EBT Margin rose 42901935.0% to 41.52% in Q4 2023 year-over-year; TTM through Sep 2024 was 138.0%, a 16234.0% increase, with the full-year FY2023 number at 43.93%, up 954907.0% from a year prior.
  • EBT Margin was 41.52% for Q4 2023 at Denali Therapeutics, up from 7841.59% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 3667.66% in Q2 2023 to a low of 429060.87% in Q4 2022.
  • A 5-year average of 37751.28% and a median of 615.76% in 2021 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: crashed -42845486bps in 2022, then soared 42901935bps in 2023.
  • Denali Therapeutics' EBT Margin stood at 204.44% in 2019, then plummeted by -544bps to 1317.26% in 2020, then skyrocketed by 54bps to 606.01% in 2021, then crashed by -70701bps to 429060.87% in 2022, then soared by 100bps to 41.52% in 2023.
  • Per Business Quant, the three most recent readings for DNLI's EBT Margin are 41.52% (Q4 2023), 7841.59% (Q3 2023), and 3667.66% (Q2 2023).